Are you at risk of ovarian cancer?

For women with a family history of ovarian, breast, or related cancers, advanced epigenetic blood-based testing may help detect ovarian cancer at earlier stages, potentially improving survival outcomes. 

  • Starts with a free 5-minute risk assessment
  • Specialist review to determine if testing may be suitable for you
  • Advanced blood-based testing for high-risk individuals
Free risk assessmentTakes 3 mins • No cost to start

In partnership with SBC High Risk Specialist Clinic.

  • Evidence-based approach
  • Specialist-led assessment
  • Privacy protected
  • Takes 5 mins • No cost
Free risk assessment

Most ovarian cancers are diagnosed at an advanced stage.²

Typical later stage diagnosis

Stage III - IV cancer
<30%1
5-year survival

Early-stage detection

Stage 1 ovarian cancer
~90%1
5-year survival
*Survival rates vary by individual and are based on published population data.

~70% of ovarian cancers are diagnosed at an advanced stage²

When it comes to ovarian cancer, earlier-stage diagnosis is usually associated with better outcomes than later-stage disease. Early detection can allow for extra review, assessment or treatment options, potentially improving survival outcomes³.

An emerging approach to clinical assessment

Advanced ovarian cancer blood-based testing is supported by clinical research and is designed to detect biological signals associated with ovarian cancer. Validation studies involving over 300 patients, including individuals from high-risk populations, demonstrated 78.2% sensitivity and 94% specificity.⁴

This type if testing may support specialist clinical decision-making for people at increased risk, when used alongside other diagnostic tools.

An emerging detection technology.

Uses a routine blood sample to support detection of ovarian cancer as part of broader clinical assessment.

Focus on early-stage
disease.

Designed to help identify cellular changes that occur early in the disease progression, when treatment outcomes may be better.

Advances in epigenetic research.

Identify signals in DNA found in the blood to help access ovarian cancer risk and support diagnosis or additional monitoring.

The limitations of current investigation methods

Ovarian cancer can be difficult to investigate because its symptoms often overlap with other common conditions5.

The CA-125 blood test is commonly used, however, it has known limitations, particularly during the early stages of ovarian cancer6. Imaging scans such as ultrasound, CT scans or MRI may also be used.

The only way to confirm an ovarian cancer diagnosis is through a biopsy, usually in surgery6.

How it works

1. Risk assessment

Answer a few short questions about your health and family history to see if additional testing may be appropriate.

2. Specialist review

If you’re identified as being at higher risk, we’ll connect you with the SBC High Risk Clinic (Sydney) for a specialist consultation.

3. Clinical assessment options

If clinically appropriate, discuss early detection options with a specialist, including this advanced ovarian cancer blood testing.

Is this testing right for you?

Some women have a higher lifetime risk of ovarian cancer due to inherited genetic factors or family history. This advanced epigenetic blood testing is designed for individuals at increased risk and offers early, non-invasive detection.

Certain inherited gene mutations, such as BRCA1 and BRCA2, are associated with a substantially higher lifetime risk of ovarian cancer compared with the general population8.
A strong family history of breast cancer and/or having one or more close family members (parents, siblings or children) diagnosed with ovarian cancer before the age of sixty can increase your risk8.

Note: A specialist can help interpret how these factors apply to your personal situation.

🧬 You have a BRCA gene mutation

If you carry a BRCA1 or BRCA2 mutation, your personal genetic risk of ovarian cancer may be significantly higher than the general population.⁷

‍👧 You have a personal or family history of ovarian cancer

A personal diagnosis or a family history of ovarian cancer can indicate inherited or familial risk8. This does not mean you will develop ovarian cancer, but it may warrant additional screening.

🧬 You have Lynch syndrome or inherited risk

Lynch syndrome is an inherited condition that increases the risk of several cancers, including ovarian cancer. Lifetime ovarian cancer risk may be higher than the general population and can occur at a younger age.7

🧬 You have a personal or family history of uterine or colorectal cancer

A personal diagnosis or family history of uterine (endometrial) or colorectal cancer may indicate an inherited cancer syndrome, such as Lynch syndrome, which is associated with an increased risk of ovarian cancer.7 8

👩‍⚕️ Your doctor recommended increased testing

If your gynaecological oncologist, genetic counsellor, or GP has recommended monitoring due to your personal or family risk factors, and you want more than CA-125 and ultrasound alone. This test can provide additional data to support clinical decision-making.

Not sure if you qualify?

Assess your risk and access specialist support if elevated
Free risk assessment

Frequently asked questions

This advanced ovarian cancer blood testing uses modern molecular and epigenetic analysis to detect biological signals associated with ovarian cancer from a simple blood sample, providing non-invasive insight for individuals at increased risk.

CA-125: Single blood marker used in ovarian cancer monitoring
This testing: Multi-signal blood analysis designed to provide additional insight for higher-risk individuals

You can speak with a specialist at the SBC High Risk Clinic to discuss your testing options in more detail.

No, routine ovarian cancer screening is not recommended for average-risk women. This testing is intended for people with elevated risk, such as those with a family history of certain cancers or inherited genetic conditions.

You’ll start by completing a short risk assessment about your health and family history to see whether additional testing may be appropriate. If you’re identified as being at higher risk, you’ll be connected with the SBC High Risk Clinic (Sydney) for a specialist consultation to book an appointment.If clinically appropriate, your specialist will discuss early detection options with you, including advanced ovarian cancer blood testing.

No, this testing does not provide a diagnosis. Results must be interpreted by a qualified healthcare professional and are used to help inform whether further evaluation or review is indicated.

The testing requires a routine blood draw from a vein. Your specialist at SBC High Risk Clinic can help you complete this during your consultation, if appropriate.

 

Traditional tools such as CA-125 blood tests and ultrasound have limited effectiveness in detecting early-stage ovarian cancer and may produce false positives.6 DNA-based blood testing uses newer molecular approaches designed to support earlier insight, particularly in higher-risk individuals.

An abnormal result does not mean you have cancer. It indicates that further review may be appropriate. Your specialist may recommend closer monitoring or additional investigations, depending on your individual risk profile. Being informed about your risk allows you and your care team to take a more proactive approach to risk management.

This test is currently fully private and paid out of pocket. We are actively working toward building a case for a Medicare rebate, however this is a complex process that typically takes several years.

It’s common for advanced and innovative healthcare tests to remain privately billed for some time before they are approved for public reimbursement. Your specialist can discuss pricing and options with you during your consultation.

Yes, this testing requires doctor authorisation and is offered through specialist consultation to make sure it’s clinically appropriate.

The initial online risk assessment takes approximately 3 minutes, and there is no cost to begin.

earlydetection.com.au is operated by BCAL Diagnostics, an Australian biotechnology company working to make advanced cancer detection tools available in Australia and New Zealand in consultation with medical specialists.

Yes. Your information is handled securely and shared only with the clinical team involved in your care.